X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1743) 1743
Publication (87) 87
Conference Proceeding (37) 37
Book Review (15) 15
Book / eBook (13) 13
Book Chapter (7) 7
Patent (5) 5
Dissertation (4) 4
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (698) 698
clinical neurology (631) 631
neurosciences (449) 449
multiple sclerosis (417) 417
index medicus (399) 399
female (372) 372
animals (308) 308
male (286) 286
adult (251) 251
middle aged (192) 192
neurology (174) 174
rats (148) 148
psychiatry (139) 139
multiple sclerosis - drug therapy (134) 134
multiple-sclerosis (131) 131
immunology (124) 124
magnetic resonance imaging (123) 123
double-blind (119) 119
treatment outcome (111) 111
therapy (110) 110
experimental autoimmune encephalomyelitis (105) 105
central-nervous-system (101) 101
aged (95) 95
multiple sclerosis - immunology (94) 94
rats, inbred lew (87) 87
medicine & public health (82) 82
research (80) 80
interferon-beta - therapeutic use (76) 76
natalizumab (76) 76
inflammation (74) 74
guillain-barre-syndrome (72) 72
adolescent (71) 71
experimental allergic encephalomyelitis (71) 71
time factors (69) 69
disease progression (68) 68
abridged index medicus (66) 66
guillain-barre syndrome (66) 66
double-blind method (63) 63
experimental allergic neuritis (63) 63
multiple sclerosis, relapsing-remitting - drug therapy (63) 63
cells, cultured (62) 62
mice (62) 62
placebo-controlled trial (60) 60
care and treatment (58) 58
cerebrospinal-fluid (58) 58
diagnosis (56) 56
disability (56) 56
disease (56) 56
glatiramer acetate (56) 56
demyelination (55) 55
t-lymphocytes - immunology (55) 55
young adult (55) 55
antibodies (53) 53
expression (53) 53
analysis (52) 52
multiple sclerosis - diagnosis (52) 52
brain - pathology (51) 51
drug therapy (51) 51
experimental autoimmune neuritis (51) 51
immunologic factors - therapeutic use (51) 51
immunotherapy (51) 51
interferon beta-1b (51) 51
risk factors (51) 51
clinical trials (50) 50
mri (50) 50
follow-up studies (48) 48
progressive multifocal leukoencephalopathy (48) 48
brain (47) 47
multicenter (47) 47
dose-response relationship, drug (46) 46
immunosuppressive agents - therapeutic use (46) 46
multiple sclerosis - therapy (46) 46
interferon (45) 45
interferon beta (44) 44
myelin basic-protein (44) 44
interferon beta-1a (43) 43
lymphocytes (43) 43
medicine, general & internal (43) 43
cells (42) 42
medicine (42) 42
guillain-barré syndrome (41) 41
multiple sclerosis - pathology (41) 41
pathology (41) 41
autoimmunity (40) 40
disability evaluation (40) 40
health aspects (40) 40
neuroradiology (40) 40
pathogenesis (40) 40
pharmacology & pharmacy (40) 40
t-cells (38) 38
tumor-necrosis-factor (37) 37
antibodies, monoclonal - therapeutic use (36) 36
intravenous immunoglobulin (36) 36
patients (36) 36
trial (36) 36
research article (35) 35
neutralizing antibodies (34) 34
fingolimod (33) 33
in-vitro (33) 33
immunohistochemistry (32) 32
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Stacks (1) 1
Online Resources - Online (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Robarts - Woodhouse Collection 13th floor (1) 1
Royal Ontario Museum - Far Eastern Egypt Folio (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Trinity College (John W Graham) - Reference (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Scarborough - Withdrawn (1) 1
Victoria University E.J. Pratt - Reference (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 209 - 220
Journal Article
Journal of Neuroinflammation, ISSN 1742-2094, 02/2016, Volume 13, Issue 1, p. 48
Background: Conditions of inflammatory tissue distress are associated with high extracellular levels of adenosine, due to increased adenosine triphosphate... 
Experimental autoimmune encephalomyelitis | Adenosine | Multiple sclerosis | ACTIVATION | BRAIN-DAMAGE | IMMUNOLOGY | NEUROSCIENCES | NEURONAL DAMAGE | GENETIC INACTIVATION | MULTIPLE-SCLEROSIS | GM-CSF | CENTRAL-NERVOUS-SYSTEM | MYELIN DEBRIS | A(2A) RECEPTOR | T-CELLS | Microglia - metabolism | Encephalomyelitis, Autoimmune, Experimental - metabolism | Peptide Fragments - toxicity | Phagocytosis - genetics | Cell Movement - genetics | Cell Movement - immunology | Myelin-Oligodendrocyte Glycoprotein - toxicity | Encephalomyelitis, Autoimmune, Experimental - chemically induced | Time Factors | Adenosine - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Receptor, Adenosine A2A - genetics | Disease Models, Animal | Cell Proliferation - genetics | Phagocytosis - drug effects | Encephalomyelitis, Autoimmune, Experimental - pathology | Cytokines - metabolism | Microglia - drug effects | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | CD4-Positive T-Lymphocytes - metabolism | Cells, Cultured | Mice, Transgenic | Up-Regulation - genetics | Receptor, Adenosine A2A - metabolism | Up-Regulation - drug effects | Cell Movement - drug effects | Macrophages - metabolism | Animals | Adenosine - analogs & derivatives | Phenethylamines - therapeutic use | Macrophages - drug effects | Cell Proliferation - drug effects | Mice | Myelin Proteolipid Protein - toxicity | CD4-Positive T-Lymphocytes - drug effects | Complications and side effects | Patient outcomes | Interferon | Dosage and administration | Inflammation | Research | Muscle proteins | Drug therapy | Adenosine triphosphate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 221 - 234
Journal Article
Clinical & Experimental Immunology, ISSN 0009-9104, 09/2018, Volume 193, Issue 3, pp. 341 - 345
Summary Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by an acute onset of severe headache and multi‐focal segmental vasoconstriction... 
RCVS | primary angiitis | CSF pleocytosis | DIAGNOSIS | SERIES | PITFALLS | CENTRAL-NERVOUS-SYSTEM | IMMUNOLOGY | Medicine, Experimental | Medical research | Vasculitis | Analysis | Vasoconstriction | Headache | Medical imaging | Angiography | Medical services | Central nervous system | Pleocytosis | Cerebrospinal fluid | Patients | Arteries | Bleeding | Immunosuppression | Nimodipine | Diagnostic systems | Original
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1503 - 1511
Journal Article
Journal of Neurology, ISSN 0340-5354, 10/2008, Volume 255, Issue 10, pp. 1449 - 1463
This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The... 
Multiple Sclerosis | Neurology | randomized trials | Neurosciences | Medicine & Public Health | glatirameracetate | treatment escalation | interferon β | immunotherapy | Neuroradiology | monoclonal antibodies | Treatment escalation | Glatirameracetate | Interferon β | Multiple sclerosis | Randomized trials | Immunotherapy | Monoclonal antibodies | interferon beta | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | NEUTRALIZING ANTIBODIES | COMBINATION THERAPY | OPEN-LABEL | INTERFERON-BETA | ANTIMYELIN ANTIBODIES | CLINICAL NEUROLOGY | DOUBLE-BLIND | INTRAVENOUS IMMUNOGLOBULIN TREATMENT | GLATIRAMER ACETATE | MITOXANTRONE-INDUCED CARDIOTOXICITY | Azathioprine - therapeutic use | Multiple Sclerosis - diagnosis | Natalizumab | Humans | Antibodies, Monoclonal - adverse effects | Health Planning Guidelines | Glatiramer Acetate | Antibodies, Monoclonal - therapeutic use | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized | Societies - standards | Mitoxantrone - therapeutic use | Antibodies, Monoclonal - pharmacology | Europe | Immunologic Factors - administration & dosage | Azathioprine - pharmacology | Immunoglobulins, Intravenous - pharmacology | Multiple Sclerosis - therapy | Peptides - pharmacology | Plasmapheresis | Randomized Controlled Trials as Topic | Magnetic Resonance Imaging | Immunoglobulins, Intravenous - therapeutic use | Interferon-beta - pharmacology | Mitoxantrone - pharmacology | Peptides - therapeutic use | Immunologic Factors - therapeutic use | Care and treatment | Health aspects | Patient outcomes
Journal Article